ARS Pharmaceuticals, Inc. Common Stock
SPRYStock
$7.46−57.49%52W
Market Cap$749.74M
P/E102.30x
Div yield—
Beta1.00
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-40.42%
Price vs S&P 500 (4W)-22.03%
VGM Score42.51
Market Capitalization$749.74M
P/E Ratio (Annual)102.30x
Earnings Surprise History
Q1 26-0.61est. -0.54
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.42
4.38
4.36
4.40
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SPRYARS Pharmaceuticals, Inc. Common Stock | D | B | D | $7.46 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
ARS Pharmaceuticals commercializes Neffy, a needle-free intranasal epinephrine treatment for Type 1 allergic reactions and anaphylaxis. The proprietary formulation combines epinephrine with an absorption enhancer to deliver efficacy comparable to injectable alternatives. Neffy is marketed globally under different trade names, including EURneffy in the European Union and United Kingdom.